Endocrinology
Conference Coverage
‘Modest’ benefit for post-MI T2D glucose monitoring
Equivocal results were seen with regard to the best method to monitor blood glucose after myocardial infarction.
FDA/CDC
Recall widens for diabetes drug metformin
More than 175 different drug combinations have been recalled since late May.
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
News
New data challenge primary care’s inattention to aldosterone in hypertension
Conference Coverage
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
Conference Coverage
Exercise cuts diabetes death risk by a third in two studies
Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.
Conference Coverage
Mega vitamin D harms bone in women, not men, without osteoporosis
News
Obesity boosts risks in COVID-19 from diagnosis to death
Excess pounds are linked to excess infection, hospitalization, ICU admission, and mortality.
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.